VCYT earnings analysis
What we found in VCYT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Veracyte (VCYT) reported strong Q1 2026 results, surpassing consensus estimates with revenue of $139.1 million and EPS of $0.52, compared to estimates of $130.4 million in revenue and $0.31 in EPS. Testing revenue grew by 26% year-over-year, reflecting solid product demand, although general and administrative expenses decreased significantly due to reallocations following restructuring efforts.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 21% YoY
- Total revenue increased by $24.6 million to $139.1 million, up 21% from Q1 2025.
- Significant EPS Beat
- EPS rose to $0.52, beating the consensus estimate of $0.31 by 0.21.
- Testing Revenue Surge of 26%
- Testing revenue reached $135.1 million, up 26% year-over-year, largely due to a 19% increase in test volume.
- Operating Income Jumps
- Income from operations increased dramatically to $22.6 million, up 680% compared to $2.9 million in Q1 2025.
- Free Cash Flow Improvement
- Free Cash Flow increased to $35.2 million in Q1 2026 from $5.4 million a year ago.
- Cash Reserves Increased
- Cash and cash equivalents totaled $439.1 million, up $26.2 million from the previous quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Restructuring Challenges
- Continued integration risks remain following the restructuring of Veracyte SAS, impacting international operations.
- Dependency on Testing Volume
- Future revenue is heavily dependent on the sustained volume of tests performed, which is subject to external factors.
- Regulatory Environment Risks
- Potential changes in government regulations or reimbursement policies could negatively affect pricing and revenue.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.52
- Gross margin
- 72.7%
- Operating margin
- 16.3%
- Segment
- Testing Revenue: $135.1M
- Segment
- Product Revenue: $3.7M
- Segment
- Biopharmaceutical and Other Revenue: $0.3M
What they said about what is next.
Raised 2026 revenue guidance to $582-$592 million from $570-$582 million.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Veracyte (VCYT) shows material operational improvement in 2025 driven by stronger test volume and margin expansion; quarterly trends show accelerating profitability and cash generation. The company is executing a clear…
- 10-Q · May 8, 2025
- Veracyte reported Q1 revenue of $114.473M (up from $96.844M a year ago) with gross profit of $79.508M and operating income of $2.904M, producing net income of $7.047M and diluted EPS of $0.09. Operating cash flow turned…
- 10-Q · November 7, 2024
- Veracyte reported a stronger Q3 with total revenue of $115,860,000 and a return to operating profitability (income from operations $12,017,000) versus an operating loss in the year-ago quarter. Gross profit rose to…
- 10-Q · August 7, 2024
- Veracyte reported better-than-expected Q2 results with revenue of $114.428M (up from $90.322M a year ago) driven by testing revenue growth. Gross profit was $77.913M (≈68.1% gross margin) and the company returned to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VCYT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever